ALK-Abelló Launches Grazax in Sweden

ALK-Abelló A/S has launched GRAZAX, the world's first tablet-based vaccine against grass pollen allergy, in Sweden. GRAZAX is the first allergy tablet that treats the underlying cause of grass pollen allergy and not just the symptoms.

The Swedish Pharmaceutical Benefits Board has decided that treatment with GRAZAX is eligible for full reimbursement under the Swedish pharmaceutical reimbursement system. The Board evaluates whether new pharmaceuticals would benefit society by evaluating the price of the pharmaceuticals relative to their effect on the health and quality of life of patients. The Benefits Board has evaluated GRAZAX vis-à-vis both traditional symptom-relieving allergy medicine and injection-based allergy vaccination. On this background, ALK-Abelló expects that patients treated with symptom-relieving medicine without satisfactory results can be offered treatment with GRAZAX.

For further information please contact:

Jacob Frische,

Director

Tel: +45 45 74 75 51

Email: jaf@dk.alk-abello.com

Or visit: www.alk-abello.com